Selumetinib

Brand: Koselugo (global)

Oncology – Targeted therapy MEK inhibitor

Chemistry

Molecular Formula	C17H17BrClFN4O3
PubChem	CID: 10127622 Open in PubChem

Structure

Half-life	7 hours
Clearance Route	hepatic
Active Metabolites	yes
Notes	Metabolized via CYP3A4 + CYP2C19 pathways; avoid strong CYP3A modulators.

Severity: Moderate

Adverse Effects:
Diarrhea, acneiform rash, fatigue, cardiomyopathy risk (↓LVEF)

Contraindications:
Severe hepatic impairment

Precautions:
Monitor LVEF baseline + follow-up; eye toxicity monitoring recommended.